IN VIVO SAFETY AND EFFICACY OF CAP FILM AND MICROBICIDE COMBINATIONS

帽膜和杀菌剂组合的体内安全性和功效

• 批准号: 8172991
• 负责人: CECILIA C CHENG-MAYER
• 金额: $ 6.18万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172991
• 关键词: Adult; Animals; Attenuated; Computer Retrieval of Information on Scientific Projects Database; Dose; Female; Film; Funding; Gel; Genes; Grant; HIV-1; Hour; Institution; Macaca; Methods; RNA-Directed DNA Polymerase; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; Vagina; Viral; Virus; in vivo; microbicide; research study; simian human immunodeficiency virus; transmission process

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Background: We proposed to establish the efficacy MIV-160 alone against simian human immunodeficiency virus containing the reverse transcriptase gene of HIV-1 (SHIV-RT). Six animals were used for this experiment. Methods: Three (3) ml of MIV-160, 500¿M/ml in hydroxymethycellulose (HEC) gel was applied vaginal into 6 adult Indian female macaques. Half -hour post gel application, each animal was challenged vaginally with 1 ml high dose 10000 TCID50 of SHIV-RT. Again, 2 ml each of MIV-160 was applied vaginally in the respective animals. 30 minutes post SHIV-RT challenge. Results/Discussion: All animals were infected. MIV-160 failed to impede transmission of the impute virus. All animals had high viral set points which indicate that MIV-160 did not alter nor attenuate SHIV-RT.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 背景资料：我们建议确定MIV-160单独对含有HIV-1逆转录酶基因的猴人类免疫缺陷病毒（SHIV-RT）的疗效。本实验使用了6只动物。 方法：将三（3）ml MIV-160，500 <$M/ml羟甲基纤维素（HEC）凝胶经阴道应用于6只成年印度雌性猕猴。凝胶施用后半小时，用1 ml高剂量10000 TCID 50的SHIV-RT经阴道攻击每只动物。 同样，在各动物中阴道施用各2 ml的MIV-160。SHIV-RT激发后30分钟。 结果/讨论：所有动物均感染。 MIV-160未能阻止插补病毒的传播。 所有动物均具有高病毒设定点，这表明MIV-160不会改变或减弱SHIV-RT。